In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Innovation Artificial Intelligence Leadership

Insitro’s Daphne Koller On The Marriage Of Biology And Machine Learning At The Company’s Heart

Instead Of Laying A Single Golden Egg, Insitro Has ‘Built A Goose’

  • Interviews

Executive Summary

Industry veteran and serial entrepreneur Daphne Koller tells In Vivo about how her company, Insitro, is unleashing the potential of computational biology and machine learning to discover new drug compounds.

Within the field of artificial intelligence, drug discovery is an area which has some of the greatest potential. In Vivo spoke with Daphne Koller, founder and CEO of insitro, about how her company is leveraging machine learning to discover new medicines.

Time stamps:

00.00 Introducing Daphne Koller

06.09 AI’s impact on drug discovery

08.26 Why drug discovery?

10.51 How insitro is advancing the field

13.55 AI vs human impact

16.22 Insuring data integrity

19.10 Partnerships in AI drug discovery

21.55 Executive moves into innovative AI

24.40 Life at insitro

Table

View full table

Topics

Tags:
Innovation Artificial Intelligence Leadership
Latest Headlines

How To Grow A Biotech - Insights From Scientist-Entrepreneurs

Vividion’s Breakthrough Science Is Fueling Bayer’s Pipeline

US FTC Targets Pharma Patent Abuse: What You Need to Know

For BMS, Launching New Products Is The Start Of The Battle

See All
UsernamePublicRestriction

Register

IV148567

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By